Warm baths for reducing seizures in CDKL5 deficiency disorder
Part of Brain & nervous system clinical trials.
This trial tests whether taking daily warm baths at home can safely reduce seizures in children with CDKL5 deficiency disorder. It may help families looking for a non-medication way to manage seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed diagnosis of CDKL5 deficiency disorder with ongoing seizures.
- Be between 6 months and 14 years old.
- Seizures are not controlled by at least two seizure medications.
- Have at least 8 visible seizures per month (based on the past 8 weeks).
- Seizure medications must stay the same for the study, unless on a stable ketogenic diet.
- A caregiver must be able to keep a daily electronic seizure diary and give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, ganaxolone, to see if it can reduce seizures in babies and toddlers with CDKL5 deficiency disorder. It aims to help children whose seizures are not controlled by current medications.
This study is for anyone diagnosed with CDKL5 disorder who can be seen at participating clinics or is already listed in an international CDKL5 registry. The goal is to help researchers better understand the condition and support future research.
This study tests a new medicine (S230815) given by lumbar puncture (spinal tap) to see if it helps reduce seizures in children with a specific genetic cause of epilepsy. It is for children aged 2 to 12 who have not responded well to other treatments.
This trial tests a drug called SVG103 (Paxalisib) in adults with brain conditions that cause hard-to-control seizures: Focal Cortical Dysplasia Type II, Tuberous Sclerosis Complex, or Hemimegalencephaly. The goal is to see if SVG103 is safe and helps reduce seizures.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This study tests a drug called phenylbutyrate for people with seizures caused by SLC6A1 gene changes. The drug may help reduce seizure frequency. The trial is fully remote, so you can join from anywhere in the U.S. without going to a clinic.
Hear when a new CDKL5 Deficiency Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.